uniQure N.V. Pension and Other Postretirement Benefits Cost (Reversal of Cost)
uniQure N.V. (QURE) reported Pension and Other Postretirement Benefits Cost (Reversal of Cost) of $3.61 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PensionAndOtherPostretirementBenefitExpense · last filed 2024-02-28
- uniQure N.V. pension and other postretirement benefits cost (reversal of cost) for fiscal 2023 was $3.61M, a 35.40% increase from fiscal 2022.
- uniQure N.V. pension and other postretirement benefits cost (reversal of cost) for fiscal 2022 was $2.67M, a 30.03% increase from fiscal 2021.
- uniQure N.V. pension and other postretirement benefits cost (reversal of cost) for fiscal 2021 was $2.05M, a 15.29% increase from fiscal 2020.
- uniQure N.V. pension and other postretirement benefits cost (reversal of cost) for fiscal 2020 was $1.78M, a 69.11% increase from fiscal 2019.
| Period end | Pension and Other Postretirement Benefits Cost (Reversal of Cost) 12 month | Pension and Other Postretirement Benefits Cost (Reversal of Cost) 12 month as first filed |
|---|---|---|
| 2023-12-31 | $3.61M 10-K · filed 2024-02-28 | |
| 2022-12-31 | $2.67M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $2.05M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $1.78M 10-K · filed 2023-02-27 | |
| 2019-12-31 | $1.05M 10-K · filed 2022-02-25 | $650.00K 10-K · filed 2020-03-02 |
| 2018-12-31 | $907.00K 10-K · filed 2021-03-01 | $628.00K 10-K · filed 2019-02-28 |
| 2017-12-31 | $802.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $1.09M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $608.00K 10-K · filed 2018-03-14 | |
| 2014-12-31 | $804.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |